Canaccord Genuity Reiterates a 'Buy' on Zalicus (ZLCS); Q1 Update: Synavive Phase 2b Enrollment Complete
Tweet
Share
E-mailGet Alerts ZLCS Hot Sheet
Price: $1.18 --0%
Rating Summary:
2 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 15 | New: 40
Rating Summary:
2 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 15 | New: 40
Join SI Premium – FREE
Canaccord Genuity reiterates a 'Buy' on Zalicus (NASDAQ: ZLCS) price target of $3.00.
Analyst, Ritu Baral, said, "Reiterate rating and price target on Synavive’s potential in rheumatoid arthritis (RA) and emerging pain platform. Synavive is ZLCS’ Ph2 drug for RA, with major market potential in various conditions treated with low dose chronic steroids. ZLCS also has a promising ion channel modulator platform for chronic pain, including Ph2a-ready Z160, a novel Ca2+ channel blocker."
For an analyst ratings summary and ratings history on Zalicus click here. For more ratings news on Zalicus click here.
Shares of Zalicus closed at $0.84 yesterday.
Analyst, Ritu Baral, said, "Reiterate rating and price target on Synavive’s potential in rheumatoid arthritis (RA) and emerging pain platform. Synavive is ZLCS’ Ph2 drug for RA, with major market potential in various conditions treated with low dose chronic steroids. ZLCS also has a promising ion channel modulator platform for chronic pain, including Ph2a-ready Z160, a novel Ca2+ channel blocker."
For an analyst ratings summary and ratings history on Zalicus click here. For more ratings news on Zalicus click here.
Shares of Zalicus closed at $0.84 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Freedom Broker Upgrades John B. Sanfilippo & Son, Inc. (JBSS) to Buy
- NetEase.com (NTES) PT Lowered to $143 at Macquarie
- GLJ Research Downgrades Fluence Energy Inc. (FLNC) to Hold
Create E-mail Alert Related Categories
Analyst CommentsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
